Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Gyan

Showing results (121-130 of 174) with videos related to

Pageof 18
Sort By:
British Journal of Haematology|July 16, 2013
Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groupsJean-Christophe Ianotto, Françoise Boyer-Perrard, Emmanuel Gyan, et al.
European Journal of Haematology|January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemiaXavier Cahu, Martin Carré, Christian Recher, et al.
Annals of Hematology|February 25, 2014
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TCCyrille Touzeau, Christophe Leux, Reda Bouabdallah, et al.
Oncogene|November 9, 2019
Correction: Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cellsFarah Kouzi, Kazem Zibara, Jerome Bourgeais, et al.
Oncogene|October 26, 2019
Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cellsFarah Kouzi, Kazem Zibara, Jerome Bourgeais, et al.
Haematologica|December 9, 2017
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) studyJean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, et al.
Blood|March 4, 2020
Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphomaMarine Baron, Lisa Belin, Nathalie Cassoux, et al.
BMC Nephrology|January 21, 2022
What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective studyJean-Michel Halimi, Benjamin Thoreau, Florent von Tokarski, et al.
Annals of Hematology|August 17, 2013
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TCCyrille Touzeau, Christophe Leux, Reda Bouabdallah, et al.
Blood Cancer Journal|April 9, 2022
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomesLéa Sureau, Caroline Buors, Jean-Christophe Ianotto, et al.
Pageof 18

Showing results (121-130 of 174) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|July 16, 2013
Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groupsJean-Christophe Ianotto, Françoise Boyer-Perrard, Emmanuel Gyan, et al.
European Journal of Haematology|January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemiaXavier Cahu, Martin Carré, Christian Recher, et al.
Annals of Hematology|February 25, 2014
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TCCyrille Touzeau, Christophe Leux, Reda Bouabdallah, et al.
Oncogene|November 9, 2019
Correction: Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cellsFarah Kouzi, Kazem Zibara, Jerome Bourgeais, et al.
Oncogene|October 26, 2019
Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cellsFarah Kouzi, Kazem Zibara, Jerome Bourgeais, et al.
Haematologica|December 9, 2017
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) studyJean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, et al.
Blood|March 4, 2020
Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphomaMarine Baron, Lisa Belin, Nathalie Cassoux, et al.
BMC Nephrology|January 21, 2022
What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective studyJean-Michel Halimi, Benjamin Thoreau, Florent von Tokarski, et al.
Annals of Hematology|August 17, 2013
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TCCyrille Touzeau, Christophe Leux, Reda Bouabdallah, et al.
Blood Cancer Journal|April 9, 2022
JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomesLéa Sureau, Caroline Buors, Jean-Christophe Ianotto, et al.
Pageof 18